5Z-7-Oxozeaenol
Based on 32 publication(s) in Google Scholar
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.30%
- CAS No.: 253863-19-3
- Formule: C19H22O7
- Masse moléculaire:362.37
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 5Z-7-Oxozeaenol
More- Nature. 2024 Apr;628(8009):835-843. [Abstract]
- Autophagy. 2025 Jan;21(1):178-190. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Sci Adv. 2025 Mar 7;11(10):eadq1047. [Abstract]
- Sci Adv. 2025 Jan 10;11(2):eadq4991. [Abstract]
- Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]
- J Immunother Cancer. 2026 Jun 3;14(6):e014253. [Abstract]
- J Exp Med. 2026 Jan 5;223(1):e20250603. [Abstract]
- Acta Pharmacol Sin. 2025 Feb;46(2):430-447. [Abstract]
- Cell Death Discov. 2021 May 8;7(1):96. [Abstract]
- Oncogene. 2026 Jun;45(23):2211-2224. [Abstract]
- Cell Rep. 2025 Mar 16;44(3):115426. [Abstract]
- Cell Rep. 2024 Nov 27;43(12):115016. [Abstract]
- Int Immunopharmacol. 2026 Mar 15:173:116271. [Abstract]
- Int Immunopharmacol. 2024 Sep 30:139:112710. [Abstract]
- Int Immunopharmacol. 2022 Mar:104:108306. [Abstract]
- J Nutr Biochem. 2026 Sep:155:110383. [Abstract]
- J Inflamm Res. 2026 Mar 16:19:574990. [Abstract]
- FASEB J. 2025 Jan 31;39(2):e70349. [Abstract]
- J Virol. 2025 Apr 15;99(4):e0208024. [Abstract]
- Viruses. 2022 Jul 7;14(7):1485. [Abstract]
- Cardiovasc Drugs Ther. 2021 Jun;35(3):599-612. [Abstract]
- Exp Eye Res. 2025 Feb:251:110232. [Abstract]
- Brain Behav. 2024 Apr;14(4):e3487. [Abstract]
- Vet Microbiol. 2021 May:256:109061. [Abstract]
- Neurosci Lett. 2022 Nov 20:791:136914. [Abstract]
- Infect Microbes Dis. 2023 Jul 24.
- bioRxiv. 2026 Jan 25.
- SSRN. 2025 Dec 2.
- McGill University. 2023 Dec.
- Research Square Preprint. 2024 Apr 15.
- Research Square Print. 2023 Mar 14.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
WB
Voir tous les produits spécifiques à Isoform MAP3K
MoreVoir tous les produits spécifiques à Isoform VEGFR
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
TAK1 8.1 nM (IC50) |
MEK1 411 nM (IC50) |
VEGFR-2 52 nM (IC50) |
VEGFR-3 110 nM (IC50) |
FLT3 170 nM (IC50) |
PDGFR-β 340 nM (IC50) |
B-RAF VE 6300 nM (IC50) |
SRC 6600 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ASPC1 | IC50 |
6020 nM
Compound: 5Z7
|
Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| BaF3 | IC50 |
12 nM
Compound: 5Z7
|
Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs in presence of IL-3 by CellTiter-Glo assay
Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs in presence of IL-3 by CellTiter-Glo assay
|
[PMID: 28038940] |
| BaF3 | IC50 |
4 nM
Compound: 5Z7
|
Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| HCT-15 | EC50 |
2 nM
Compound: 1
|
Cytotoxicity against TNFalpha-induced human HCT-15 cells assessed as reduction in cell viability preincubated for 2 hrs followed by TNFalpha stimulation and measured after 72 hrs by celltiter-glo assay
Cytotoxicity against TNFalpha-induced human HCT-15 cells assessed as reduction in cell viability preincubated for 2 hrs followed by TNFalpha stimulation and measured after 72 hrs by celltiter-glo assay
|
[PMID: 33859795] |
| HeLa | IC50 |
0.25 μM
Compound: 5
|
Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA
Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA
|
[PMID: 21513293] |
| HT-29 | IC50 |
3.6 μM
Compound: 5
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| MCF7 | IC50 |
3.8 μM
Compound: 5
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| MDA-MB-435 | IC50 |
3.3 μM
Compound: 5
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| NCI-H23 | IC50 |
1 μM
Compound: 5Z7
|
Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| NCI-H460 | IC50 |
1.2 μM
Compound: 5
|
Cytotoxicity against human H460 cells after 72 hrs by MTS assay
Cytotoxicity against human H460 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| PANC-1 | IC50 |
2500 nM
Compound: 5Z7
|
Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| SF-268 | IC50 |
5.1 μM
Compound: 5
|
Cytotoxicity against human SF268 cells after 72 hrs by MTS assay
Cytotoxicity against human SF268 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| Sf9 | IC50 |
8.1 nM
Compound: 1
|
Inhibition of TAK1 (unknown origin) expressed in sf9 cells assessed as 32P level incorporation into myelin basic protein incubated for 5 mins at 30 degC by immunoprecipitation method
Inhibition of TAK1 (unknown origin) expressed in sf9 cells assessed as 32P level incorporation into myelin basic protein incubated for 5 mins at 30 degC by immunoprecipitation method
|
[PMID: 26481152] |
| SK-CO-1 | IC50 |
250 nM
Compound: 5Z7
|
Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| SW-620 | IC50 |
2540 nM
Compound: 5Z7
|
Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay
|
[PMID: 28038940] |
| THP-1 | IC50 |
11 nM
Compound: 1, f152A1
|
Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production by PLAP reporter assay
Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production by PLAP reporter assay
|
[PMID: 19783437] |
5Z-7-Oxozeaenol is a potent irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 (TAK1, IC50, 8.1 nM), less active on MEK1 (IC50, 411 nM). 5Z-7-Oxozeaenol prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase[1]. 5Z-7-Oxozeaenol is also an inhibitor of VEGF-R2, with an IC50 of 52 nM. 5Z-7-Oxozeaenol has inhibitory activity against VEGF-R3, FLT3, PDGFR-β, B-RAF VE and SRC, with IC50s of 110, 170, 340, 6300 and 6600 nM, respectively[2]. 5Z-7-Oxozeaenol inhibits JNK/p38 paythway, but it is not a direct inhibitor and is signal specific. 5Z-7-Oxozeaenol suppresses the PMA-induced AP-1 activity almost to the basal level in the KT cells, but has no effects on IL-1-induced NF-kB activity in the KK cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 253863-19-3
-
Appearance Solid
-
Masse moléculaire 362.37
-
Formule C19H22O7
-
Color White to off-white
-
SMILES
O=C(O[C@@H](C)C/C=C\1)C2=C(O)C=C(OC)C=C2/C=C/C[C@H](O)[C@H](O)C1=O
-
Synonyms
FR148083; L783279; LL-Z 1640-2
-
Structure Classification
-
Initial Source
Cochliobolus lunatus
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Apr;628(8009):835-843. PMID: 38600381 -
Autophagy
TRIM21-mediated ubiquitination of SQSTM1/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity. [Abstract]2025 Jan;21(1):178-190. PMID: 39172027 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Sci Adv
TBK1 and IKKε prevent premature cell death by limiting the activity of both RIPK1 and NLRP3 death pathways. [Abstract]2025 Mar 7;11(10):eadq1047. PMID: 40053580 -
Sci Adv
Tgfβ signaling stimulates glycolysis to promote the genesis of synovial joint interzone in developing mouse embryonic limbs. [Abstract]2025 Jan 10;11(2):eadq4991. PMID: 39772668 -
Cell Death Dis
GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway. [Abstract]2022 Apr 30;13(4):421. PMID: 35490166
5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]
5Z-7-oxozeaenol（iTAK1, 5 mg/kg; i.p.; once daily for 4 weeks)-induced histological changes in heart sections stained with H&E and WGA to analyze heart and cardiomyocyte size, respectively. (n = 6-7 mice/group).
5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]
Effects of 5Z-7-oxozeaenol（iTAK1, 5 mg/kg; i.p.; once daily for 4 weeks) on EF, FS, and LVESd values in GCN5-overexpressing mice and control mice after sham or TAC surgery (n = 6–7 mice/group).
-
J Immunother Cancer
Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer. [Abstract]2026 Jun 3;14(6):e014253. PMID: 42236112 -
J Exp Med
Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1. [Abstract]2026 Jan 5;223(1):e20250603. PMID: 41081715
5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: J Exp Med. 2026 Jan 5;223(1):e20250603. [Abstract]
The cells were stimulated by Flag-TNFα (100 ng/ml) after pretreatment of 5Z-7-Oxozeaenol (5z7, 500 nM) for 30 min. After stimulation for indicated periods, complex I was immunoprecipitated with Flag antibody. Relative levels of TNFR1, p-RIPK1 (S166), RIPK1, TRADD in complex I or whole-cell lysates were measured with immunoblotting.
5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: J Exp Med. 2026 Jan 5;223(1):e20250603. [Abstract]
Ripk1−/− MEFs were reconstituted with WT or R606K mutant Flag-RIPK1 by lentivirus. The cells were subsequently treated with 5Z-7-Oxozeaenol (5z7, 500 nM)/TNFα (10 ng/mL) for the indicated time in the presence or absence of Nec-1s (10 μM). Cell death was measured by the SYTOX Green positivity assay.
-
Acta Pharmacol Sin
Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages. [Abstract]2025 Feb;46(2):430-447. PMID: 39223367 -
Cell Death Discov
Silencing TAK1 reduces MAPKs-MMP2/9 expression to reduce inflammation-driven neurohistological disruption post spinal cord injury. [Abstract]2021 May 8;7(1):96. PMID: 33966042 -
Oncogene
Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. [Abstract]2026 Jun;45(23):2211-2224. PMID: 42032367 -
Cell Rep
2025 Mar 16;44(3):115426. PMID: 40096087 -
Cell Rep
Unveiling the physiological impact of ESCRT-dependent autophagosome closure by targeting the VPS37A ubiquitin E2 variant-like domain. [Abstract]2024 Nov 27;43(12):115016. PMID: 39607828 -
Int Immunopharmacol
Luteolin mitigates inflammatory organ injury by targeting XIAP to block PANoptosis and mitochondrial dysfunction. [Abstract]2026 Mar 15:173:116271. PMID: 41637826 -
Int Immunopharmacol
Scutellarin inhibits inflammatory PANoptosis by diminishing mitochondrial ROS generation and blocking PANoptosome formation. [Abstract]2024 Sep 30:139:112710. PMID: 39029229 -
Int Immunopharmacol
Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. [Abstract]2022 Mar:104:108306. PMID: 34999396 -
J Nutr Biochem
Therapeutic potential of wogonoside in hypertension-induced cardiac injury: Targeting apoptosis and MAPK signaling pathway. [Abstract]2026 Sep:155:110383. PMID: 41990999 -
J Inflamm Res
Integrated Multi-Omics Analysis Reveals IRF1-Driven Microglial PANoptosis via ZBP1 in Spinal Cord Injury. [Abstract]2026 Mar 16:19:574990. PMID: 41867458 -
FASEB J
Betaine-homocysteine methyltransferase attenuates liver ischemia-reperfusion injury by targeting TAK1. [Abstract]2025 Jan 31;39(2):e70349. PMID: 39854060 -
J Virol
African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly. [Abstract]2025 Apr 15;99(4):e0208024. PMID: 40135893 -
Viruses
Inducible miR-150 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Genome and Suppressor of Cytokine Signaling 1. [Abstract]2022 Jul 7;14(7):1485. PMID: 35891465 -
Cardiovasc Drugs Ther
2021 Jun;35(3):599-612. PMID: 32495070 -
Exp Eye Res
Senescent retinal pigment epithelial cells promote angiogenesis in choroidal neovascularization via the TAK1/p38 MAPK pathway. [Abstract]2025 Feb:251:110232. PMID: 39778673 -
Brain Behav
5Z-7-Oxozaenol attenuates cuprizone-induced demyelination in mice through microglia polarization regulation. [Abstract]2024 Apr;14(4):e3487. PMID: 38648385 -
Vet Microbiol
Highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) induces IL-6 production through TAK-1/JNK/AP-1 and TAK-1/NF-κB signaling pathways. [Abstract]2021 May:256:109061. PMID: 33836390 -
Neurosci Lett
Deficiency of CD93 exacerbates inflammation-induced activation and migration of BV2 microglia by regulating the TAK1/NF-κB pathway. [Abstract]2022 Nov 20:791:136914. PMID: 36270452
5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2022 Nov 20:791:136914. [Abstract]
5Z-7-oxozeaenol (10 nM) significantly inhibits LPS-induced high expression of NF-κB and TAK1 in microglial.
-
-
-
-
-
-
Solvant et solubilité
DMSO : 30 mg/mL (82.79 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
For screening TAK1 inhibitors, insect expression vectors for TAK1 and TAB1 are co-infected into Sf9 cells. After 2 days of incubation, cell lysates are immunoprecipitated with anti-TAK1 antibody (M-17). The immunoprecipitates are incubated with various compounds (5Z-7-Oxozeaenol, etc.) and subsequently incubated with 2 μg of myelin basic protein and 10 μCi of [γ-32P]ATP (3,000 Ci/mmol) in 10 μL of the kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl2 at 30°C for 5 min. Samples are separated by 10% SDS-PAGE, and 32P incorporated into myelin basic protein is quantified with a bioimage analyzer. The catalytic activity of MEK1 is determined by activation of ERK2 to phosphorylate dure. The catalytic activity of MEKK1 is measured with 2 μg of myelin basic protein as a substrate in the kinase buffer. For subsequent kinase assays, immunoprecipitates are incubated with 5 μCi of [γ-32P]ATP (3,000 Ci/mmol) and 1 μg of bacterially expressed MKK6 or GST-IκBα-(1-72) in 10 μL of the kinase buffer at 25°C for 2 min. Samples are separated by 10% SDS-PAGE and visualized by autoradiography[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ninomiya-Tsuji J, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem. 2003 May 16;278(20):18485-90. [Content Brief]
[2]. Dakas PY, et al. Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. Angew Chem Int Ed Engl. 2007;46(36):6899-902. [Content Brief]
[3]. Takehana K, et al. A radicicol-related macrocyclic nonaketide compound, antibiotic LL-Z1640-2, inhibits the JNK/p38 pathways in signal-specific manner. Biochem Biophys Res Commun. 1999 Apr 2;257(1):19-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7596 mL | 13.7981 mL | 27.5961 mL | 68.9903 mL |
| 5 mM | 0.5519 mL | 2.7596 mL | 5.5192 mL | 13.7981 mL | |
| 10 mM | 0.2760 mL | 1.3798 mL | 2.7596 mL | 6.8990 mL | |
| 15 mM | 0.1840 mL | 0.9199 mL | 1.8397 mL | 4.5994 mL | |
| 20 mM | 0.1380 mL | 0.6899 mL | 1.3798 mL | 3.4495 mL | |
| 25 mM | 0.1104 mL | 0.5519 mL | 1.1038 mL | 2.7596 mL | |
| 30 mM | 0.0920 mL | 0.4599 mL | 0.9199 mL | 2.2997 mL | |
| 40 mM | 0.0690 mL | 0.3450 mL | 0.6899 mL | 1.7248 mL | |
| 50 mM | 0.0552 mL | 0.2760 mL | 0.5519 mL | 1.3798 mL | |
| 60 mM | 0.0460 mL | 0.2300 mL | 0.4599 mL | 1.1498 mL | |
| 80 mM | 0.0345 mL | 0.1725 mL | 0.3450 mL | 0.8624 mL |
5Z-7-Oxozeaenol Related Classifications
HY-12686 Related Classifications
Powered by Bioz